The efficacy and safety of sitagliptin administration in patients with Covid-19: A randomized clinical trial

The efficacy and safety of sitagliptin administration in patients with Covid-19: A randomized clinical trial

Blog Article

Background: Coronavirus disease was associated with read more a high risk of mortality, especially among patients with underlying diseases.Effective treatments against Covid-19 could complement vaccination efforts worldwide.Methods: To determine the efficacy of Sitagliptin in the treatment of COVID-19.

Randomized clinical trial study with a control group that was conducted on 40 covidd-19 patients.Block randomization method was used.The participants were divided into two groups (group A receiving Sitagliptin tablet at dose of 50 mg BID for 10 days and the group B receiving standard treatment without sitagliptin).

Descriptive statistics such as mean and standard deviation, ratio, frequency table and percentage were used to describe the data, and chi-square test, independent t test and one- way ANOVA were used to analyze the data.SPSS v.25 software was used for data analysis.

The significance level in the tests was considered 0.05.Results: A significant difference was observed between the improvements of the total clinical score in the two groups, so that the people who used Sitagliptin received a higher clinical score; On the other hand, among the 20 patients who were in the control group, 18 patients were discharged bilstein shocks jeep xj from the hospital on the 7th day or earlier.

Sitagliptin has an anti-inflammatory, antifibrotic and antiapoptotic properties; such effects may be beneficial in reducing risks of COVID-19.Conclusions: Sitagliptin also provides good safety and fair benefits to reduce mortality among DM patients with COVID-19.